Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioavailability and Palatability of BMS-986165 Pediatric Formulation in Healthy Adults
NCT04305899Phase 1Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Aug 2020
- Primary completion
- Nov 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of deucravacitinib in plaque psoriasis (10 arms), sponsored by Bristol Myers Squibb. Primary endpoints: Maximum concentration in plasma up to 26 days, Area under the plasma concentration-time curve from time 0 to the last quantifiable concentration up to 26 days and 1 more. Started Aug 2020; status: completed.
02
Drugs
deucravacitinib
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on NCT04305899.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04305899.